

Submitted to Molecular Medicine Reports

The essential oil of *Foeniculum vulgare* subsp. *piperitum* fruits exerts anti-tumor activity in triple negative breast cancer cells.

Running Title: LAURICELLA et al. ANTI-CANCER EFFECTS OF THE ESSENTIAL OIL OF FOENICULUM VULGARE SUBSP. PIPERITUM

Key Words: essential oil; phytochemicals, antitumor effect; breast cancer; apoptotic cell death

Submitted by: Antonella D'Anneo, received on 22-03-2022

Type of Article: Article

Abstract

Nowadays, the growing spread of tumor cases worldwide makes the research of new promising and selective anticancer drugs an urgent need. On this subject the interest on the biological action of extracts of medicinal plants or their essential oils is emerging since they could represent a rich source of phytochemicals that deserve particular attention and need to be investigated. In this paper we explored the biological activity and the mechanism of action of the essential oil of *Foeniculum vulgare* subsp. *piperitum* fruits (FVPEO) in MDA-MB231, a triple negative breast cancer cell line. Our analysis provided evidence that FVPEO is endowed with particularly strong anticancer capabilities, causing a dose-dependent growth inhibition of breast cancer MDA-MB231 cells accompanied to DNA condensation and fragmentation. The cytotoxic effect of FVPEO was counteracted by the addition of the antioxidant N-acetylcysteine (NAC) and was associated to a remarkable ROS increase and stress-related proteins such as MnSOD, c-Jun, pJNK, Nrf2 and its transcriptional targets (HO-1, NQO1). As evidenced by the activation of caspase-3 and fragmentation of PARP-1, typical apoptosis markers, FVPEO promoted an apoptotic cell death program that was accompanied to an increase in phosphorylated H2AX and to the activation of NQO1/p53 axis. Taken together, our analyses provided evidence that FVPEO could represent a reservoir of biologically active compounds suitable for both prevention and cancer treatment.

Authors

Name	Institute	Email Address
Professor Marianna Lauricella	Department of Biomedicine, Neurosciences and Advanced Diagnostics (BIND), Institute of Biochemistry, University of Palermo	marianna.lauricella@unipa.it
Professor Antonella Maggio [Corresponding]	Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo	antonella.maggio@unipa.it
Dr Natale Badalamenti	Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo	natale.badalamenti@unipa.it
Professor Maurizio Bruno	Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo	maurizio.bruno@unipa.it
Dr Giovanni Danilo D'Angelo	Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo	giovannidanilo.dangelo@community.unipa.it
Professor Antonella D'Anneo [Corresponding]	Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo	antonella.danneo@unipa.it

Files

File Name	Type	Uploaded
Cover letter MMR 20 03 2022.docx	Letter to the Editor	20-03-2022
Manuscript.doc	Manuscript	20-03-2022
Figure 1.tif	Figures and Images	20-03-2022
Figure 2.tif	Figures and Images	20-03-2022
Figure 3.tif	Figures and Images	20-03-2022
Figure 4.tif	Figures and Images	20-03-2022
Figura 5.tif	Figures and Images	20-03-2022
Figure 6.tif	Figures and Images	20-03-2022

1 **The essential oil of *Foeniculum vulgare* subsp. *piperitum* fruits exerts anti-tumor**
2 **activity in triple negative breast cancer cells.**

3 Marianna Lauricella^a, Antonella Maggio^{b*}, Natale Badalamenti^b, Maurizio Bruno^b, Giovanni Danilo
4 D'Angelo^c and Antonella D'Anneo^{c*}.

5 ^a Department of Biomedicine, Neurosciences and Advanced Diagnostics (BIND), Institute of
6 Biochemistry, University of Palermo, 90127 Palermo, Italy.

7 ^b Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF),
8 University of Palermo, Viale delle Scienze, ed. 17, I-90128 Palermo, Italy.

9 ^c Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF),
10 Laboratory of Biochemistry, University of Palermo, 90127 Palermo, Italy.

11 *Corresponding authors: antonella.danneo@unipa.it, antonella.maggio@unipa.it (for chemical
12 aspects)

13 *Abbreviations*: essential oil of *Foeniculum vulgare* subsp. *piperitum* fruits (FVPEO); essential oils (Eos) the
14 triple-negative breast cancer (TNBC).

15 *Keywords*: essential oil; phytochemicals, antitumor effect; breast cancer; apoptotic cell death

16 **Running title**: LAURICELLA et al. ANTI-CANCER EFFECTS OF THE ESSENTIAL OIL OF
17 *FOENICULUM VULGARE* SUBSP. *PIPERITUM*

18 Abstract

19 Nowadays, the growing spread of tumor cases worldwide makes the research of new promising and
20 selective anticancer drugs an urgent need. On this subject the interest on the biological action of
21 extracts of medicinal plants or their essential oils is emerging since they could represent a rich
22 source of phytochemicals that deserve particular attention and need to be investigated. In this paper
23 we explored the biological activity and the mechanism of action of the essential oil of *Foeniculum*
24 *vulgare* subsp. *piperitum* fruits (FVPEO) in MDA-MB231, a triple negative breast cancer cell line.
25 Our analysis provided evidence that FVPEO is endowed with particularly strong anticancer
26 capabilities, causing a dose-dependent growth inhibition of breast cancer MDA-MB231 cells
27 accompanied to DNA condensation and fragmentation. The cytotoxic effect of FVPEO was
28 counteracted by the addition of the antioxidant N-acetylcysteine (NAC) and was associated to a
29 remarkable ROS increase and stress-related proteins such as MnSOD, c-Jun, pJNK, Nrf2 and its
30 transcriptional targets (HO-1, NQO1). As evidenced by the activation of caspase-3 and
31 fragmentation of PARP-1, typical apoptosis markers, FVPEO promoted an apoptotic cell death
32 program that was accompanied to an increase in phosphorylated H2AX and to the activation of
33 NQO1/p53 axis.

34 Taken together, our analyses provided evidence that FVPEO could represent a reservoir of
35 biologically active compounds suitable for both prevention and cancer treatment.

36 Introduction

37 *Foeniculum vulgare* Mill. (*F. vulgare*), commonly named fennel, is one of the most widespread
38 aromatic plants. This species belongs to the Apiaceae family and it is widely cultivated throughout
39 different parts of world as Asia, North and South America, and in the Southern regions of Europe
40 (1).

41 The plant offers many different edible parts as leaves, stalks and seeds (fruits) that represent a
42 source of a wide range of phytochemicals like fatty acids, phenolic compounds, and flavonoids as
43 well as volatile compounds, such as anethole, estragole, and fenchone, as major phytoconstituents
44 (2,3). Mostly of these phytochemicals are found in essential oils (EOs) appearing practically in any
45 part of the plant, as root, stem, seed and fruit (4).

46 *F. vulgare* fruits are commonly used as a culinary spice. The EOs from fennel are often used as
47 flavoring agents, but also as constituents of cosmetic and pharmaceutical products (5).

48 *F. vulgare* is widely used in traditional medicine for its ability of exerting diuretic, antispasmodic,
49 analgesic, mucolytic, and anti-inflammatory effects (1). Its stems, fruits, leaves, seeds and whole
50 plant itself are used to treat a wide range of ailments of digestive, reproductive and respiratory
51 systems, including abdominal pains, constipation, diarrhea, amenorrhea, fever, flatulence, arthritis,
52 insomnia, irritable colon, liver pain, mouth ulcer, and stomachache (1,6–8). In ancient China its use
53 found application as remedy for snake bite, and in addition the infusion of fruits was applied as
54 carminative, while roots revealed to possess efficient purgative properties. In some parts of
55 Southern Italy the decoction of the fruits of *F. vulgare* subsp. *piperitum* is used as digestive or,
56 chewing its leaves is considered a cure for mouth ulcers (9). Furthermore, it has been prescribed as
57 a muscle relaxant, a weak diuretic, carminative, and a mild stimulant (10).

58 The genus *Foeniculum* is present in Italy with only one species, that has been divided into two
59 subspecies, *Foeniculum vulgare* subsp. *vulgare* Miller and *Foeniculum vulgare* subsp. *piperitum*
60 (Ucria) Coutinho. This distinction is still a subject of debate among botanists. In fact, on the basis of
61 the different distribution, some botanists believe that they represent two distinct species. The certain
62 presence of *F. vulgare* subsp. *piperitum* is reported in Central-Southern Mediterranean, but outside
63 this area the species is quite rare. Furthermore, this subspecies does not contain anethole (11) and it
64 is often confused with a chemotype of *F. vulgare* var. *vulgare*, which presents a bitter, but different
65 taste.

66 Recently, the chemical compositions of the EOs of different vegetative parts of *F. vulgare* subsp.
67 *piperitum* collected in Sicily were evaluated by GC and GC-MS (12). The results were compared

68 with those of the EOs of the same vegetative parts of *F. vulgare* subsp. *vulgare*, collected in the
69 same station and with those reported in literature for other accessions of *F. vulgare* subsp.
70 *piperitum*. The oils of *F. vulgare* subsp. *vulgare* showed completely different compositions clearly
71 indicating the differentiation of the two subspecies.

72 A number of studies performed in *in vitro* and *in vivo* models highlighted how various extracts of *F.*
73 *vulgare* possess antioxidant, anti-inflammatory, anti-mutagenic and anticancer properties. *F.*
74 *vulgare* EOs showed anti-mutagenic effects in mice where it reduced chromosomal aberrations
75 induced in mouse bone marrow cells by cyclophosphamide. This effect was mediated by a
76 reduction of oxidative stress (13). The anti-tumor activity of *F. vulgare* has been shown against
77 different cancer cells, such as melanoma (14), prostate (15), lung cancer (16), and epatocarcinoma
78 cells (17). Ke et al demonstrated that ethanol extract of *F. vulgare* seeds induced apoptosis in HCI-
79 H446 and NCI-H661 lung cancer cell lines as well as inhibited the growth of NCI-446-derived
80 xenografts by reducing Bcl-2 protein expression (16). Extracts of *F. vulgare* seeds also induced
81 apoptosis and inhibited cell migration of hepatocarcinoma cells *in vitro* and significantly
82 constrained the growth of HCC xenografts in nude mice by targeting survivin (17). In addition,
83 extracts of *F. vulgare* seeds also exerted anticancer effect on Elrich ascites carcinoma-bearing mice
84 by modulating lipid peroxidation and potentiating antioxidant defense (18).

85 Thus, based on the promising previous results concerning the anti-cancer potential of *F. vulgare*, we
86 sought to examine the possible anti-cancer action of essential oil of *F. vulgare* subsp. *piperitum*
87 (FVPEO) in triple negative MDA-MB231 breast cancer cells, demonstrating that FVPEO induces
88 an apoptotic cell death process through the activation of NQO1/p53 axis.

89 **Materials and Methods**

90 *F. vulgare* subsp. *piperitum*: *plant material and fruits essential oil preparation*. Fruits of *F. vulgare*
91 subsp. *piperitum* were collected on the southern slopes of the limestone massif of Rocca Busambra
92 (Corleone, Palermo, Italy). Typical specimens (PAL 109709), identified by Prof. Vincenzo Ilardi,
93 have been deposited in Herbarium Mediterraneum Panormitanum of the “Orto Botanico”, Palermo,
94 Italy. One hundred thirty-six grams (135 g) of *F. vulgare* subsp. *piperitum* fruits was hydro-
95 distilled for 3 h using Clevenger’s apparatus. The oil (yield 1.36 %) was dried with Na₂SO₄,
96 filtered, and stored in the freezer at 20 °C, until the time of analysis. The chemical composition of
97 FVPEO was performed as previously reported (12).

98 *Cell cultures, reagents, and chemicals*. Triple negative breast cancer MDA-MB231 cells, obtained
99 from “Istituto Scientifico Tumori” (Genoa, Italy), were cultured as monolayers in DMEM medium
100 supplemented with 10% (v/v) heat-inactivated FCS, 1% non-essential amino acids, 2mM glutamine
101 and 1% penicillin/streptomycin solution. Cells were plated on 96 well plates or on 100-mm culture
102 dishes, then were allowed to adhere overnight in culture medium at 37 °C in a humidified
103 atmosphere containing 5% CO₂, before the treatment with FVPEO or vehicle only. Media as well as
104 cell culture reagents were purchased from Euroclone. All other chemicals and reagents were
105 provided by Sigma-Aldrich (Milan, Italy).

106 *Cell viability assessment and morphological detection of apoptosis*. In order to assess cell viability
107 of breast cancer cells exposed to FVPEO treatment, MTT test was performed as previously reported
108 (19). For assays, cells (8x10³/well) were plated in 200 µL of DMEM in a 96-well plate and exposed
109 to the treatment. At the end, 4 µL of MTT solution (5 mg/mL in PBS) were added to the cell
110 medium and the incubation was protracted for 2 h at 37 °C in the dark. Mitochondria
111 dehydrogenase activity of viable cells converts MTT to formazan, which is soluble in tissue culture
112 medium. At the end cells were lysed in lysis buffer and the absorbance was read at 570 and 690 nm
113 by an automatic ELISA plate reader (OPSYS MR, Dynex Technologies, Chantilly, VA).

114 In order to determine either changes in nuclear morphology or plasma membrane damage, the cells
115 were stained with Hoechst 33342, a cell permeant fluorochrome emitting blue fluorescence when
116 bound to dsDNA and excited by ultraviolet light. For these assays, cells (8x10³) were incubated in
117 the presence of Hoechst 33342 (2.5 µg/mL medium) for 30 min, washed with PBS and suspended
118 in culture medium before FVPEO treatment. Morphological detection of apoptotic cells evidenced

119 by chromatin condensation as well as fragmentation was analyzed by fluorescence microscopy
120 using an excitation wavelength of 372 nm and an emission wavelength of 456 nm. All the pictures
121 were taken by Leica Q Fluoro Software. For the analysis at least 10 fields for each sample were
122 considered and apoptotic cells were counted in random fields using a 100x magnification.
123 The apoptotic cell morphology was also studied by acridine orange and ethidium bromide (AO/EB)
124 double staining as reported by Wu et al. (20).

125 *Analysis of reactive oxygen species generation.* The detection of intracellular reactive oxygen
126 species production was carried out by H₂-DCFDA staining as previously reported (21). H₂-DCFDA
127 is a non-polar dye that easily crosses cell membrane and can be oxidized to DCFDA in the presence
128 of ROS remaining entrapped into the cells and emitting green fluorescence.
129 After incubating the cells in the presence of FVPEO, medium was removed and cells were
130 incubated in the presence of 10 μM H₂-DCFDA (Molecular Probe, Life Technologies, Eugene, OR,
131 USA) for 30 min at 37 °C. Then positive cells were analyzed under a Leica fluorescence
132 microscope with excitation at 485 nm and emission at 530 nm as previously reported (22).

133 *Western blotting analysis.* For western blotting analyses, cells were lysed in RIPA lysis buffer
134 containing 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% sodium dodecyl sulfate, 0.5% sodium
135 deoxycholate, 1 mM EDTA supplemented with phosphatase inhibitor mix (Sigma, Dallas, TX,
136 USA). Extracts were sonicated thrice and protein content was determined by Bradford assay using
137 an albumin bovine serum (BSA, Sigma Aldrich) standard curve. Then, 30 μg/lane of protein sample
138 were subjected to SDS polyacrylamide gel electrophoresis and transferred to a nitrocellulose
139 membrane. The analyses of MnSOD, c-Jun, pJNK, NQO1, γ-H2AX, p53, pro-caspase-3 and
140 PARP-1 were performed by using specific antibodies produced by Santa Cruz Biotechnology (Santa
141 Cruz, CA). As for as HO-1 analyses the antibody (orb5455) was provided by Biorbyt Ltd
142 (Cambridge, United Kingdom), while Nrf-2 antibody (NBP1-32822) purchased from Novus
143 Biologicals (Bio-Techne SRL, Milan, Italy).

144 Protein bands were detected by the Enhanced chemiluminescence reagent (Amersham Biosciences,
145 GE Healthcare Life Science, Milan, Italy), and quantified by using Quantity One software (Bio-
146 Rad, Hercules, CA). The correct protein loading was checked by immunoblotting for γ-tubulin. All
147 the blots shown are representative of at least three separate experiments.

148 *Statistics.* Statistical analysis of data was performed by Graphpad Prism 5.0. software (GraphPad
149 Prism™ Software Inc, San Diego, CA). Data were expressed as means \pm SD. The statistical
150 significance threshold was set at $p < 0.05$.

151 **Results**

152 *Chemical profiling of essential oil of F. vulgare subsp. piperitum.*

153 Hydro distillation of the fruits of *F. vulgare subsp. piperitum* gave a pale-yellow oil. The essential
154 oil composition was previously reported (12).

155 As reported in the pie chart of Figure 1, FVFEO was particularly rich in monoterpene hydrocarbons
156 71.01% with terpinolene (20.10%), limonene (17.84%), α -phellandrene (10.53%) and γ -terpinene
157 (10.43%) as the main components. The second most abundant class was the phenylpropanoids,
158 typical metabolites of *F. vulgare subsp. vulgare* (12), is quite poor (14.36%), with estragole
159 (10.96%) and myristicin (3.09%) as major products. Oxygenated monoterpenes were present in
160 lower amount (10.78%) with fenchone (8.83%) as principal metabolites of this class.

161 Based on these observations, we explored whether FVFEO could exert a biological activity
162 evaluating its putative anti-tumor potential.

163 *Effects of FVPEO on the viability of MDA-MB231 breast cancer cells*

164 To demonstrate a possible anti-proliferative effect of the essential oil of the fruits of *F. vulgare*
165 subsp. *piperitum* (FVPEO) we focused our study on MDA-MB231, a very aggressive and poorly
166 differentiated breast cancer cell line, which does not express estrogen, progesterone and
167 HER-2/receptors (23). MDA-MB231 cells were treated with increasing concentrations (within the
168 range of 125-2000 $\mu\text{g/mL}$) of FVPEO for various periods and the viability was assessed by MTT
169 assay, as reported in Methods. As reported in Fig.2A, the cell survival rate displayed a remarkable
170 dose- and time-dependent decrease after FVPEO treatment compared to untreated control. After 24
171 h of treatment the viability of MDA-MB231 cells was reduced by 20% of control with 125 $\mu\text{g/mL}$
172 FVPEO. Increasing the dose of treatment, the viability diminished progressively and a consistent
173 cytotoxic effect was reached at the highest concentration examined (only about 5% of viable cells
174 with 2000 $\mu\text{g/mL}$). The cytotoxic effect of FVPEO further increased prolonging the time of
175 treatment up to 48 h, when the viability lowered to 15% with 500 $\mu\text{g/mL}$ FVPEO.

176 Light microscopy observations showed that following exposure to FVPEO, MDA-MB231 cells
177 underwent morphological changes. As shown in Fig. 2B, cells treated with lower doses (125-250
178 $\mu\text{g/mL}$) of FVPEO appeared elongated in comparison to untreated cells. Increasing the dose of
179 FVPEO, the typical morphological changes of apoptotic cells, as cell shrinkage and roundness,
180 appeared and a marked reduction of cell number was observed.

181 *FVPEO-induced cytotoxic effect is counteracted by the antioxidant N-acetylcysteine and ~~was~~ is*
182 *accompanied by ROS generation*

183 We next examined whether the cytotoxic effect of FVPEO was dependent on oxidative stress. To
184 this end, MDA-MB231 cells were pre-incubated for 2 h with *N*-acetylcysteine (NAC), a ROS
185 scavenger; then different doses of FVPEO were added for another 24 h. Our data demonstrated that
186 the addition of NAC counteracted the cytotoxic effect of FVPEO. In particular, as shown in Fig.
187 3A, 10 mM NAC prevented the cytotoxic effect induced by low concentrations (125-250 $\mu\text{g}/\text{mL}$) of
188 FVPEO and importantly reduced that of high concentrations (500-1000 $\mu\text{g}/\text{mL}$) of the compound.
189 To better explore these effects we also evaluated the generation of ROS by H2DCFDA, a
190 fluorochrome that binds ROS and emits green fluorescence in the oxidized form. Using such an
191 experimental approach we observed a clear rise in green fluorescence indicative of ROS production
192 in FVPEO-treated cells (Figure 3B). The increase, that already appeared at 30 min of incubation
193 with 250 and 500 $\mu\text{g}/\text{ml}$ FVPEO, reached a maximum level at 60 min after application. Then,
194 western blotting analyses were also performed to evaluate whether FVPEO treatment modified the
195 level of MnSOD, one of the main cellular antioxidant enzymes (24). As shown in Fig. 3 B, an
196 increased level of MnSOD was observed only after treatment with lower doses of FVPEO (125-250
197 $\mu\text{g}/\text{mL}$).

198 *FVPEO cytotoxic effect is mediated by oxidative stress and upregulation of stress-associated*
199 *proteins.*

200 In light of the observed data demonstrating ROS production in MDA-MB231-treated cells we
201 explored whether the cytotoxic effect induced by FVPEO can be accompanied by the activation of
202 stress associated proteins (Figure 4).

203 Firstly, we analysed the level of c-Jun and phospho-JNK (pJNK). c-Jun is a member of the
204 activating protein (AP-1) transcription factor that can be activated in response to different
205 extracellular stimuli such as pro-inflammatory cytokines, UV radiation and many different forms of
206 cellular stress (25). Its activation has been correlated to the signalling of c-Jun N-terminal kinases
207 (JNKs), a family of stress mediated kinases capable of integrating many different cellular stimuli
208 such as mitogenic signals, environmental stresses, and different apoptotic insults (26).

209 Our data provided evidence that FVPEO treatment caused a modest increase in pJNK, but a
210 consistent increase in c-Jun level that was already visible at 24 h with 250 $\mu\text{g}/\text{mL}$ dose and further
211 increased for longer periods of incubation.

212 The involvement of stress in FVPEO-treated cells was also confirmed by the upregulation of Nrf2
213 (NF-E2 p45-related factor 2), a transcription factor that has been considered one of the main
214 regulatory factors of redox homeostasis that controls a battery of detoxification and cytoprotective
215 genes (27). In our experimental conditions, we observed in FVPEO-treated cells an increase in Nrf-
216 2 content that was associated to an upregulation of its target genes Heme oxygenase (HO-1) and
217 NADPH quinone oxidoreductase 1 (NQO1).

218 *FVPEO induces apoptosis in MDA-MB231 cells*

219 To investigate whether the loss of viability of MDA-MB231 cells under FVPEO treatment was due
220 to the induction of apoptosis, cells were stained with Hoechst 33342, a fluorescent dye that binds to
221 DNA and permits to identify nuclear apoptotic changes. According to fluorescence microscopy
222 images, MDA-MB231 cells treated with FVPEO exhibited a clear nuclear fragmentation and
223 condensation, compared with control untreated cells (Fig. 5A). The proportion of cells with
224 condensed and fragmented nuclei increased with the dose of FVPEO treatment (Fig. 5B). Such an
225 effect was also confirmed by acridine orange/ethidium bromide dual staining showing the presence
226 of typical morphological features of apoptosis in MDA-MB231 treated cells (Figure 5C). Indeed,
227 some FVPEO- treated cells resulted positive to a yellow-green acridine orange nuclear staining
228 (early apoptotic cells) and a remarkable percentage of them showed a concentrated orange nuclear
229 ethidium bromide staining (late apoptotic cells).

230 *FVPEO induces a p53-dependent intrinsic apoptotic pathway in MDA-MB231 cells.*

231 To further explore the underlying mechanism of FVPEO-induced apoptosis, we examined whether
232 the observed effects and associated with DNA injury can be accompanied to the recruitment of
233 DNA damage markers. When a double-strand break occurs in DNA, alteration in chromatin
234 structure promotes the phosphorylation of the histone variant H2AX at the Ser-139 residue (28).
235 This event is induced by the kinases [ATM](#), [ATR](#) and [DNA-PK](#), allowing the formation of γ H2AX
236 (H2AX phosphorylated on serine 139), that is thus considered a marker of DNA damage (29). Our
237 data demonstrated that treatment of MDA-MB231 cells with FVPEO induced a strong
238 phosphorylation of H2AX at Ser139 (γ H2AX) in a dose-dependent manner (Fig. 6).
239 We next examined possible changes in the level of p53 protein, a key factor involved in the
240 induction of apoptosis in response to DNA damage (30). The same Fig. 6 showed that the level of
241 p53 markedly increased in MDA-MB231- treated cells compared with untreated control.

242 In our study we also analysed the effect of FVPEO on caspase-3, a key mediator of apoptosis of
243 mammalian cells whose activation by cleavage of pro-caspase is responsible for chromatin
244 condensation (31). Our results indicated that FVPEO treatment induced a dose-dependent decrease
245 of the inactive procaspase-3, indicating the activation of caspase-3 (Fig.6). This suggestion was
246 validated by the cleavage of PARP-1, a well-known target of caspase-3 (32), observed after FVPEO
247 treatment. Taken together these data indicated that FVPEO induced a caspase-dependent apoptosis
248 triggered by a DNA damage.

249 Discussion

250 Nowadays, the increasing number of cancer cases around the world makes the research of specific
251 and targeted therapies an urgent global need at medical level. On this scenario a particular attention
252 has been addressed on the vegetal kingdom as a possible bio-resource where to research new
253 phytochemicals as preventative or protective compounds to apply to cancer therapies alone or in
254 combination (33–35). Indeed, from their discovery to the cancer research application along the
255 years a vast array of plant derived phytochemicals have been identified as etoposide, taxol,
256 doxorubicin, topotecan, irinotecan and camptotecin that have been revealed to be valuable and
257 highly effective chemotherapeutics routinely applied in clinical practice (36). More than three
258 quarters of anti-cancer chemotherapeutics currently used in medicine are natural products or their
259 analogues chemically modified with active pharmacophores to enhance their anti-tumor potential
260 (37).

261 In light of these considerations, we undertook a study to evaluate the possible anti-cancer properties
262 of essential oils of *F. vulgare* subsp. *piperitum* (FVPEO) grown on the Sicilian rural areas. Our
263 previous studies highlighted the composition of the most abundant secondary metabolites present in
264 FVPEO (12) and since no data are available on the biological activity of the FVPEO grown in
265 Sicily so far, we aimed at investigating whether it can exert anti-proliferative effects in triple
266 negative breast cancer cells.

267 Breast cancer is one of the most spread tumor affecting women, incidence tends to rise with age and
268 ranks the second leading cause of death (38,39). On the basis of the presence or absence of
269 estrogen, progesterone and human epidermal growth factor 2 (HER2) receptor, this tumor has been
270 classified into the three distinct subtypes that present different percentage of distribution in affected
271 women. In particular, the hormone receptor positive/ERBB2 negative form affects up to 70% of
272 patients, the ERBB2 positive form concerns the 15%-20% of cases, and the triple-negative (TNBC)
273 subtype, characterized by the lack of all receptors, affects about 15% of patients (40). In particular,
274 a focal point of concern for breast cancer incidence has been posed for TNBC. It is the most
275 aggressive breast cancer form, for which the poor prognosis, the highly invasive profile as well as
276 the development of a remarkable resistance to the most common cancer therapies still represent the
277 main challenges in the fight of this form of tumor (41).

278 Our data demonstrated that FVPEO induced a remarkable reduction of cell viability in triple
279 negative breast cancer cells and such an effect was associated to oxidative injury as evidenced by a
280 consistent ROS generation. As it is well known ROS are highly reactive molecules that, when

281 produced at physiological level in the cell, can participate to intracellular signaling functioning as
282 redox messenger (42). However, the generation of ROS at high doses turns to be dangerous for the
283 cells, since their production overcomes intracellular scavenger systems triggering cell death (43). In
284 accordance with these observations, our data provided evidence that ROS production induced by
285 FVPEO treatment up surged stress-associated proteins such as c-Jun, pJNK as well as that of
286 antioxidant defense systems represented Nrf-2 (Nuclear factor E2-related factor 2) and its targets
287 MnSOD and NQO1.

288 Nrf-2 is a transcription factor that under stress condition shuttles from cytosol to nucleus where
289 promotes the basal and stress-inducible expression of a plethora of cytoprotective enzymes (44)
290 involved in glutathione metabolism (components of glutamate-cysteine ligase complex),
291 thioredoxin antioxidants based response (thioredoxin, sulfiredoxin), ROS and xenobiotic
292 detoxification (NADPH quinone dehydrogenase 1 (NQO1); glutathione peroxidase 2 (Gpx2) and
293 several glutathione S-transferases) and iron metabolism (Heme-oxygenase (HO-1)).

294 In our experimental conditions Nrf-2 upregulation induced by FVPEO treatment was associated to
295 an increased level of HO-1 and NQO1.

296 NQO1 has been described as a putative anti-tumor factor (45) involved in ROS removal, so that the
297 application of phytochemicals or plant-derived compounds to promote NQO1 upregulation has
298 been indicated as a putative chemopreventive strategy for cancer (46). These evidences seem to
299 sustain the mode of action of FVPEO in breast cancer cells reported in this paper. Indeed we
300 demonstrated that FVPEO promoted a remarkable DNA condensation and fragmentation with
301 activation of caspase-3 and PARP-1 fragmentation. The cell death induced by FVPEO seems to be
302 correlated with ROS increase, as suggested by the observation that the effect of FVPEO on the
303 reduction of cell viability was counteracted by the anti-oxidant NAC. In response to FVPEO-
304 induced DNA damage the apoptotic cell death was accompanied by p53 and γ -H2AX upregulation,
305 two typical markers of DNA damage. In accordance with Patino-Morales data (47) the increase of
306 NQO1 and p53 level seemed to be tightly related each other. These authors demonstrated the
307 existence of a tight interplay between NQO1 and p53, aimed at stabilizing p53 half-life and
308 favoring its role in the induction of apoptotic cell demise.

309 Mechanistic studies by El Garawani et al. (48) reported that a combination of oils of *F. vulgare* and
310 *P. graveolens* exerts a remarkable cytotoxic effects towards breast cancer MCF-7 cells through
311 cell cycle arrest, while no cytotoxicity was observed on normal human peripheral blood
312 lymphocytes in vitro. The cytotoxic effect of these essential oils was attributed by Garavani to

313 anethole and estragole which represent the main constituents present found in their experimental
314 conditions.

315 In conclusion our data suggested that FVPEO exerts a marked apoptotic effect on triple negative
316 breast cancer cells, which seems to be correlated with ROS increase, whose level overwhelms the
317 ability of antioxidant systems, such as Nrf2, HO-1 and NQO1, to counteract them. The increase in
318 the level of the antioxidant enzyme NQO1 could also favor p53 stabilization induced by DNA
319 damage, thus contributing to the apoptotic cell death.

320 **Funding** This work was supported by grant from MIUR-ITALY PRIN 2017 (Project N.
321 2017A95NCJ) and partially sustained by the Fondo Finalizzato per la Ricerca di Ateneo FFR
322 2018/2021 (FFR-D15-009169 Università degli Studi di Palermo).

323 **Availability of data and materials**

324 The data used and/or analyzed during the present study are available from the corresponding
325 authors on reasonable request.

326 **Authors' contributions**

327 A.D., M.L., A.M. and M.B. conceived and designed the experiments. M.L., N.B. and D.G. D'A.
328 conducted all the experiments. M.L., A.M. and A.D. acquired and analyzed the data. M.L., A.M.
329 and A.D. wrote and revised the manuscript. All authors read and approved the final version of
330 manuscript.

331 **Competing interests**

332 The authors declare that they have no competing interests.

333 **References**

- 334 1. Badgujar, S.B.; Patel, V.V.; Bandivdekar, A.H. *Foeniculum vulgare* Mill: A Review of Its
335 Botany, Phytochemistry, Pharmacology, Contemporary Application, and Toxicology. *BioMed*
336 *Res. Int.* **2014**, *2014*, 1–32, doi:10.1155/2014/842674.
- 337 2. Chanchal Garg, S A Khan; , S. H. Ansari; , Arti Suman; , Munish Garg Chemical Composition,
338 Therapeutic Potential and Perspectives of *Foeniculum vulgare*. *Pharmacogn. Rev.* **2009**, *3*, 346-
339 352.
- 340 3. Weiping He and Baokang Huang A Review of Chemistry and Bioactivities of a Medicinal
341 Spice: *Foeniculum Vulgare*. *J. Med. Plants Res.* **2011**, *5*, 3595–3600.
- 342 4. Díaz-Maroto, M.C.; Pérez-Coello, M.S.; Esteban, J.; Sanz, J. Comparison of the Volatile
343 Composition of Wild Fennel Samples (*Foeniculum vulgare* Mill.) from Central Spain. *J. Agric.*
344 *Food Chem.* **2006**, *54*, 6814–6818, doi:10.1021/jf0609532.
- 345 5. Guillén, M.D.; Manzanos, M.J. A Study of Several Parts of the Plant *Foeniculum vulgare* as a
346 Source of Compounds with Industrial Interest. *Food Res. Int.* **1996**, *29*, 85–88,
347 doi:10.1016/0963-9969(95)00047-X.
- 348 6. Guarrera, P.M.; Savo, V. Perceived Health Properties of Wild and Cultivated Food Plants in
349 Local and Popular Traditions of Italy: A Review. *J. Ethnopharmacol.* **2013**, *146*, 659–680,
350 doi:10.1016/j.jep.2013.01.036.
- 351 7. Rahimi, R.; Ardekani, M.R.S. Medicinal Properties of *Foeniculum vulgare* Mill. in Traditional
352 Iranian Medicine and Modern Phytotherapy. *Chin. J. Integr. Med.* **2013**, *19*, 73–79,
353 doi:10.1007/s11655-013-1327-0.
- 354 8. Amini, F.; Marzban, M.; Salehi, A. The Effect of *Foeniculum vulgare* on Dysmenorrhea; a
355 Systematic Review. *Planta Med.* **2016**, *81*, S1–S381, doi:10.1055/s-0036-1596972.
- 356 9. Guarrera, P.M.; Salerno, G.; Caneva, G. Folk. Phytotherapeutical Plants from Maratea Area
357 (Basilicata, Italy). *J. Ethnopharmacol.* **2005**, *99*, 367–378, doi:10.1016/j.jep.2005.01.039.
- 358 10. Musa Özcan, M.; Claude Chalchat, J. Effect of Collection Time on Chemical Composition of
359 the Essential Oil of *Foeniculum vulgare* subsp. *piperitum* Growing Wild in Turkey. *Eur. Food*
360 *Res. Technol.* **2006**, *224*, 279–281, doi:10.1007/s00217-006-0309-x.
- 361 11. Muckensturm, B.; Foechterlen, D.; Reduron, J.-P.; Danton, P.; Hildenbrand, M. Phytochemical
362 and Chemotaxonomic Studies of *Foeniculum vulgare*. *Biochem. Syst. Ecol.* **1997**, *25*, 353–358,
363 doi:10.1016/S0305-1978(96)00106-8.
- 364 12. Ilardi, V.; Badalamenti, N.; Bruno, M. Chemical Composition of the Essential Oil from
365 Different Vegetative Parts of *Foeniculum vulgare* subsp . *piperitum* (Ucria) Coutinho

- 366 (Umbelliferae) Growing Wild in Sicily. *Nat. Prod. Res.* **2021**, 1–11,
367 doi:10.1080/14786419.2020.1870227.
- 368 13. Tripathi, P.; Tripathi, R.; Patel, R.K.; Pancholi, S.S. Investigation of Antimutagenic Potential of
369 *Foeniculum vulgare* Essential Oil on Cyclophosphamide Induced Genotoxicity and Oxidative
370 Stress in Mice. *Drug Chem. Toxicol.* **2013**, *36*, 35–41, doi:10.3109/01480545.2011.648328.
- 371 14. Madhulika Pradhan, S Sribhuwaneswari, D Karthikeyan, Sunita Minz, Pavani Sure, Atul N
372 Chandu, Umesh Mishra, K Kamalakannan, A Saravanankumar, T Sivakumar In-Vitro
373 Cytoprotection Activity of *Foeniculum vulgare* and *Helicteres isora* in Cultured Human Blood
374 Lymphocytes and Antitumour Activity against B16F10 Melanoma Cell Line. *Res. J. Pharm.*
375 *Technol.* **2008**, *1*.
- 376 15. Elkady, A.I. Anethole Inhibits the Proliferation of Human Prostate Cancer Cells via Induction
377 of Cell Cycle Arrest and Apoptosis. *Anticancer Agents Med. Chem.* **2018**, *18*, 216–236,
378 doi:10.2174/1871520617666170725165717.
- 379 16. Ke, W.; Zhao, X.; Lu, Z. *Foeniculum vulgare* Seed Extract Induces Apoptosis in Lung Cancer
380 Cells Partly through the Down-Regulation of Bcl-2. *Biomed. Pharmacother.* **2021**, *135*,
381 111213, doi:10.1016/j.biopha.2020.111213.
- 382 17. Ke, W.; Wang, H.; Zhao, X.; Lu, Z. *Foeniculum vulgare* Seed Extract Exerts Anti-Cancer
383 Effects on Hepatocellular Carcinoma. *Food Funct.* **2021**, *12*, 1482–1497,
384 doi:10.1039/D0FO02243H.
- 385 18. Mohamad, R.H.; El-Bastawesy, A.M.; Abdel-Monem, M.G.; Noor, A.M.; Al-Mehdar, H.A.R.;
386 Sharawy, S.M.; El-Merzabani, M.M. Antioxidant and Anticarcinogenic Effects of Methanolic
387 Extract and Volatile Oil of Fennel Seeds (*Foeniculum vulgare*). *J. Med. Food* **2011**, *14*, 986–
388 1001, doi:10.1089/jmf.2008.0255.
- 389 19. Lo Galbo, V.; Lauricella, M.; Giuliano, M.; Emanuele, S.; Carlisi, D.; Calvaruso, G.; De Blasio,
390 A.; Di Liberto, D.; D’Anneo, A. Redox Imbalance and Mitochondrial Release of Apoptogenic
391 Factors at the Forefront of the Antitumor Action of Mango Peel Extract. *Molecules* **2021**, *26*,
392 4328, doi:10.3390/molecules26144328.
- 393 20. Wu, X. Dual AO/EB Staining to Detect Apoptosis in Osteosarcoma Cells Compared with Flow
394 Cytometry. *Med. Sci. Monit. Basic Res.* **2015**, *21*, 15–20, doi:10.12659/MSMBR.893327.
- 395 21. Pratelli, G.; Carlisi, D.; D’Anneo, A.; Maggio, A.; Emanuele, S.; Palumbo Piccionello, A.;
396 Giuliano, M.; De Blasio, A.; Calvaruso, G.; Lauricella, M. Bio-Waste Products of *Mangifera*
397 *indica* L. Reduce Adipogenesis and Exert Antioxidant Effects on 3T3-L1 Cells. *Antioxidants*
398 **2022**, *11*, 363, doi:10.3390/antiox11020363.

- 399 22. Lauricella, M.; Lo Galbo, V.; Cernigliaro, C.; Maggio, A.; Palumbo Piccionello, A.; Calvaruso,
400 G.; Carlisi, D.; Emanuele, S.; Giuliano, M.; D'Anneo, A. The Anti-Cancer Effect of *Mangifera*
401 *indica* L. Peel Extract Is Associated to γ H2AX-Mediated Apoptosis in Colon Cancer Cells.
402 *Antioxidants* **2019**, *8*, 422, doi:10.3390/antiox8100422.
- 403 23. Hero, T.; Bühler, H.; Kouam, P.N.; Priesch-Grzeszowiak, B.; Lateit, T.; Adamietz, I.A. The
404 Triple-Negative Breast Cancer Cell Line MDA-MB 231 Is Specifically Inhibited by the
405 Ionophore Salinomycin. *Anticancer Res.* **2019**, *39*, 2821–2827, doi:10.21873/anticancer.13410.
- 406 24. Kahl, R.; Kampkötter, A.; Wätjen, W.; Chovolou, Y. Antioxidant Enzymes and Apoptosis.
407 *Drug Metab. Rev.* **2004**, *36*, 747–762, doi:10.1081/DMR-200033488.
- 408 25. Meng, Q.; Xia, Y. C-Jun, at the Crossroad of the Signaling Network. *Protein Cell* **2011**, *2*, 889–
409 898, doi:10.1007/s13238-011-1113-3.
- 410 26. Chen, Y.-R.; Meyer, C.F.; Tan, T.-H. Persistent Activation of C-Jun N-Terminal Kinase 1
411 (JNK1) in γ Radiation-Induced Apoptosis. *J. Biol. Chem.* **1996**, *271*, 631–634,
412 doi:10.1074/jbc.271.2.631.
- 413 27. Bellezza, I.; Giambanco, I.; Minelli, A.; Donato, R. Nrf2-Keap1 Signaling in Oxidative and
414 Reductive Stress. *Biochim. Biophys. Acta BBA - Mol. Cell Res.* **2018**, *1865*, 721–733,
415 doi:10.1016/j.bbamer.2018.02.010.
- 416 28. Zhao, H.; Huang, X.; Halicka, H.D.; Darzynkiewicz, Z. Detection of Histone H2AX
417 Phosphorylation on Ser-139 as an Indicator of DNA Damage. *Curr. Protoc. Cytom.* **2019**, *89*,
418 doi:10.1002/cpcy.55.
- 419 29. Burma, S.; Chen, B.P.; Murphy, M.; Kurimasa, A.; Chen, D.J. ATM Phosphorylates Histone
420 H2AX in Response to DNA Double-Strand Breaks. *J. Biol. Chem.* **2001**, *276*, 42462–42467,
421 doi:10.1074/jbc.C100466200.
- 422 30. Chen, J. The Cell-Cycle Arrest and Apoptotic Functions of P53 in Tumor Initiation and
423 Progression. *Cold Spring Harb. Perspect. Med.* **2016**, *6*, a026104,
424 doi:10.1101/cshperspect.a026104.
- 425 31. Porter, A.G.; Jänicke, R.U. Emerging Roles of Caspase-3 in Apoptosis. *Cell Death Differ.* **1999**,
426 *6*, 99–104, doi:10.1038/sj.cdd.4400476.
- 427 32. Chaitanya, G.V.; Alexander, J.S.; Babu, P.P. PARP-1 Cleavage Fragments: Signatures of Cell-
428 Death Proteases in Neurodegeneration. *Cell Commun. Signal.* **2010**, *8*, 31, doi:10.1186/1478-
429 811X-8-31.

- 430 33. Lauricella, M.; Emanuele, S.; Calvaruso, G.; Giuliano, M.; D'Anneo, A. Multifaceted Health
431 Benefits of *Mangifera indica* L. (Mango): The Inestimable Value of Orchards Recently Planted
432 in Sicilian Rural Areas. *Nutrients* **2017**, *9*, 525, doi:10.3390/nu9050525.
- 433 34. Emanuele, S.; Notaro, A.; Palumbo Piccionello, A.; Maggio, A.; Lauricella, M.; D'Anneo, A.;
434 Cernigliaro, C.; Calvaruso, G.; Giuliano, M. Sicilian Litchi Fruit Extracts Induce Autophagy
435 versus Apoptosis Switch in Human Colon Cancer Cells. *Nutrients* **2018**, *10*, 1490,
436 doi:10.3390/nu10101490.
- 437 35. Allegra, M.; D'Anneo, A.; Frazzitta, A.; Restivo, I.; Livrea, M.A.; Attanzio, A.; Tesoriere, L.
438 The Phytochemical Indicaxanthin Synergistically Enhances Cisplatin-Induced Apoptosis in
439 HeLa Cells via Oxidative Stress-Dependent P53/P21waf1 Axis. *Biomolecules* **2020**, *10*, 994,
440 doi:10.3390/biom10070994.
- 441 36. Demain, A.L.; Vaishnav, P. Natural Products for Cancer Chemotherapy: Natural Products -
442 Cancer. *Microb. Biotechnol.* **2011**, *4*, 687–699, doi:10.1111/j.1751-7915.2010.00221.x.
- 443 37. Dholwani, K.; Saluja, A.; Gupta, A.; Shah, D. A Review on Plant-Derived Natural Products and
444 Their Analogs with Anti-Tumor Activity. *Indian J. Pharmacol.* **2008**, *40*, 49, doi:10.4103/0253-
445 7613.41038.
- 446 38. Ataollahi, M.R.; Sharifi, J.; Paknahad, M.R.; Paknahad, A. Breast Cancer and Associated
447 Factors: A Review. *J. Med. Life* **2015**, *8*, 6–11.
- 448 39. Fahad Ullah, M. Breast Cancer: Current Perspectives on the Disease Status. In *Breast Cancer*
449 *Metastasis and Drug Resistance*; Ahmad, A., Ed.; Advances in Experimental Medicine and
450 Biology; Springer International Publishing: Cham, 2019; Vol. 1152, pp. 51–64 ISBN 978-3-
451 030-20300-9.
- 452 40. Waks, A.G.; Winer, E.P. Breast Cancer Treatment: A Review. *JAMA* **2019**, *321*, 288,
453 doi:10.1001/jama.2018.19323.
- 454 41. Medina, M.A.; Oza, G.; Sharma, A.; Arriaga, L.G.; Hernández Hernández, J.M.; Rotello, V.M.;
455 Ramirez, J.T. Triple-Negative Breast Cancer: A Review of Conventional and Advanced
456 Therapeutic Strategies. *Int. J. Environ. Res. Public Health* **2020**, *17*, 2078,
457 doi:10.3390/ijerph17062078.
- 458 42. Emanuele, S.; D'Anneo, A.; Calvaruso, G.; Cernigliaro, C.; Giuliano, M.; Lauricella, M. The
459 Double-Edged Sword Profile of Redox Signaling: Oxidative Events As Molecular Switches in
460 the Balance between Cell Physiology and Cancer. *Chem. Res. Toxicol.* **2018**, *31*, 201–210,
461 doi:10.1021/acs.chemrestox.7b00311.

- 462 43. Ghosh, N.; Das, A.; Chaffee, S.; Roy, S.; Sen, C.K. Reactive Oxygen Species, Oxidative
463 Damage and Cell Death. In *Immunity and Inflammation in Health and Disease*; Elsevier, 2018;
464 pp. 45–55 ISBN 978-0-12-805417-8.
- 465 44. Tonelli, C.; Chio, I.I.C.; Tuveson, D.A. Transcriptional Regulation by Nrf2. *Antioxid. Redox*
466 *Signal.* **2018**, *29*, 1727–1745, doi:10.1089/ars.2017.7342.
- 467 45. Mizumoto, A.; Ohashi, S.; Kamada, M.; Saito, T.; Nakai, Y.; Baba, K.; Hirohashi, K.; Mitani,
468 Y.; Kikuchi, O.; Matsubara, J.; et al. Combination Treatment with Highly Bioavailable
469 Curcumin and NQO1 Inhibitor Exhibits Potent Antitumor Effects on Esophageal Squamous
470 Cell Carcinoma. *J. Gastroenterol.* **2019**, *54*, 687–698, doi:10.1007/s00535-019-01549-x.
- 471 46. Braicu, C.; Mehterov, N.; Vladimirov, B.; Sarafian, V.; Nabavi, S.M.; Atanasov, A.G.;
472 Berindan-Neagoe, I. Nutrigenomics in Cancer: Revisiting the Effects of Natural Compounds.
473 *Semin. Cancer Biol.* **2017**, *46*, 84–106, doi:10.1016/j.semcancer.2017.06.011.
- 474 47. Patiño-Morales, C.C.; Soto-Reyes, E.; Arechaga-Ocampo, E.; Ortiz-Sánchez, E.; Antonio-
475 Véjar, V.; Pedraza-Chaverri, J.; García-Carrancá, A. Curcumin Stabilizes P53 by Interaction
476 with NAD(P)H:Quinone Oxidoreductase 1 in Tumor-Derived Cell Lines. *Redox Biol.* **2020**, *28*,
477 101320, doi:10.1016/j.redox.2019.101320.
- 478 48. El-Garawani, I.; El Nabi, S.H.; Nafie, E.; Almeldin, S. *Foeniculum vulgare* and *Pelargonium*
479 *graveolens* Essential Oil Mixture Triggers the Cell Cycle Arrest and Apoptosis in MCF-7 Cells.
480 *Anticancer Agents Med. Chem.* **2019**, *19*, 1103–1113,
481 doi:10.2174/1573399815666190326115116.
- 482

483 Legends of Figures

484 **Figure 1. Chemical composition of essential oil of *F. vulgare* subsp. *piperitum* fruits.** The
485 chemical profiling of the main constituents of essential oil of *F. vulgare* subsp. *piperitum* was
486 performed as reported in methods.

487 **Figure 2 Essential oil of *F. vulgare* subsp. *piperitum* fruit induced cytotoxic effects and**
488 **morphological changes in MDA-MB231 breast cancer cells.** (A) Dose and time dependence of
489 FVPEO effect on cell viability. MDA-MB231 cells (8×10^3) were incubated in the presence of
490 various doses of essential oil of *Foeniculum vulgare* subsp. *piperitum* fruits (FVPEO) (125-2000
491 $\mu\text{g/mL}$) at the indicated times. Cell viability was assessed by MTT assay and expressed as the
492 percentage of the viable control cells. Values are the means of three independent experiments \pm S.E.
493 (*) $p < 0.05$, (**) $p < 0.01$, compared to the control. (B) Morphological changes of MDA-MB231
494 cells treated for 24 h with different concentrations of FVPEO observed under light microscopy. The
495 results are representative of three independent experiments.

496 **Figure 3. Protective effects of N-acetylcysteine against FVPEO-induced cytotoxic effects.**

497 (A) The antioxidant N-acetylcysteine counteracts the cytotoxic effects of FVPEO on MDA-MB231
498 cells. Cells (8×10^3) were incubated with different concentrations of FVPEO alone or in the
499 presence of N-acetylcysteine (NAC). After 24h of treatment the viability was assessed by MTT
500 assay and expressed as percentage of control cells. Values are the means of three independent
501 experiments \pm S.E. (*) $p < 0.05$ compared to the control. (#) $p < 0.05$, (##) $p < 0.01$ compared to
502 FVPEO -treated sample.

503 (B) FVPEO treatment increased intracellular ROS detected using the redox-sensitive fluorochrome
504 H₂-DCFDA. After treatment with FVPEO per different time, the medium was replaced with 10 μM
505 H₂DCFDA solution and the incubation was protracted for 30 min at 37 °C. The oxidation of the
506 fluorochrome generates green fluorescence, which was visualized by a Leica microscope equipped
507 with a DC300F camera using a FITC filter. Representative micrographs of fluorescence microscopy
508 were taken at x200 magnification. (C) FVPEO treatment increased the level of the anti-oxidant
509 enzyme MnSOD. MDA-MB231 cells (2×10^5) were treated for 24 h in the presence of different
510 concentrations of FVPEO. Then, cell lysates were analyzed using Western blotting with specific
511 antibody directed against MnSOD. The data are representative blots of three independent


512 experiments. Densitometry analysis histogram normalized to γ -tubulin is reported. (*) $p < 0.05$
513 compared to the control.


514 **Figure 4. FVPEO upregulates the level of stress proteins and antioxidant factors.** Cell lysates
515 of MDA-MB231 cells were prepared after the incubation in the presence of FVPEO for 24 and 48 h
516 respectively. The expression of stress proteins (c-Jun and pJNK) as well as antioxidant factors
517 (Nrf2, HO-1 and NQO1) was analyzed by western blotting using specific antibodies as reported in
518 methods section. The equal loading of proteins was ascertained by probing the blot with γ -tubulin
519 antibody. The data are representative blots of three independent experiments. Densitometry analysis
520 histograms normalized to γ -tubulin are reported in the bottom panel. (*) $p < 0.05$, (**) $p < 0.01$,
521 (***) $p < 0.001$ compared to the control.


522 **Figure 5. FVPEO induces apoptosis in MDA-MB231 cells.** (A) MDA-MB231 cells (8×10^3)
523 were stained with Hoechst 33342 (2.5 mg/mL medium; blue fluorescence) and then treated with
524 different concentrations of FVPEO for 24 h. Cell morphology was visualized with a Leica DC 300F
525 microscope with fluorescent filters for DAPI. The image shows that FVPEO treatment induced the
526 appearance of cells with condensed and fragmented chromatin. (B) Cells with condensed and
527 fragmented chromatin were counted in three different microscopic fields in each well (three wells
528 for each treatment) and expressed as percentage of the total number of cells counted in the field.
529 Values reported in the figure as percentage of apoptotic cells per total number of cells per field are
530 the mean of three independent experiments. (*) $p < 0.05$, (**) $p < 0.01$, compared to the control.
531 (C) MDA-MB231 cells (8×10^3) were treated with different concentrations of FVPEO for 24 h and
532 then stained with acridine orange/ethidium bromide dual staining as reported in methods. The image
533 shows that FVPEO treatment induced the appearance of some cells positive to a yellow-green
534 acridine orange nuclear staining (early apoptotic cells) and a remarkable percentage of cells with
535 orange nuclear ethidium bromide staining (late apoptotic cells).


536 **Figure 6 FVPEO effects on DNA damage markers, caspase activation and PARP-1**
537 **fragmentation.** MDA-MB231 cells (2×10^5) were treated for 24 h in the presence of different
538 concentrations of FVPEO. Then, cell lysates were analyzed using Western blotting with specific
539 antibodies directed against phosphorylated H2AX (γ H2AX), p53, pro-caspase-3 and PARP-1, as
540 reported in Materials and Methods. The data are representative blots of three independent

541 experiments. Densitometry analysis histograms normalized to γ -tubulin are reported in the bottom
542 panel. (*) $p < 0.05$ compared to the control.


**Figure 1**

**Figure 2**




**Figure 4**

A



B



C





Figure 5

**Figure 6**